Connect with us

Potential COVID treatment under development in St. Pete

June 23, 2020 - ViralClear Pharmaceuticals has signed an agreement with Catalent to work on the development of a potential treatment for adults with COVID-19. Under terms of the deal, Catalent will develop  two oral dosage forms of ViralClear's broad-spectrum anti-viral agent, merimepodib. ViralClear, a subsidiary of BioSig Technologies (Nasdaq: BSGM) is investigating the potential of merimepodib to fight the SARS-CoV-2 virus, either as a standalone treatment or in combination with other anti-viral agents or immune modulators, a news release said. The work will take place at Catalent's 453,000-square-foot manufacturing plant in St. Petersburg. It's the primary softgel development and manufacturing facility in the U.S. for Catalent (NYSE: CTLT), a contract development and manufacturing company based in Somerset, New Jersey. Catalent has several other deals with biopharma companies working on COVID-19 treatments and vaccines, including an agreement with Johnson & Johnson (NYSE: JNJ). Under that deal, Catalent would use its plant in Bloomington, Indiana for commercial manufacturing of J&J's lead COVID-19 vaccine candidate.

More Zaps Frontpage

The St. Pete Catalyst

The Catalyst honors its name by aggregating & curating the sparks that propel the St Pete engine.  It is a modern news platform, powered by community sourced content and augmented with directed coverage.  Bring your news, your perspective and your spark to the St Pete Catalyst and take your seat at the table.

Email us:

Subscribe for Free

Share with friend

Enter the details of the person you want to share this article with.